Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC

Taysha Gene Therapies (NASDAQ:TSHA) had its price objective boosted by Needham & Company LLC from $10.00 to $12.00 in a research note released on Thursday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Chardan Capital reissued a “buy” rating and set a $12.00 price target on shares of Taysha Gene Therapies in a research report on Thursday. Wells Fargo & Company increased their target price on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Monday, December 29th. The Goldman Sachs Group set a $11.00 price objective on Taysha Gene Therapies in a research report on Thursday, December 4th. Finally, Wall Street Zen lowered Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, January 3rd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Taysha Gene Therapies has an average rating of “Moderate Buy” and an average price target of $11.09.

Taysha Gene Therapies Stock Up 2.5%

TSHA opened at $4.56 on Thursday. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $6.02. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23. The business’s 50-day moving average price is $4.65 and its 200-day moving average price is $4.53. The company has a market cap of $1.25 billion, a P/E ratio of -13.82 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%.The business had revenue of $5.49 million for the quarter, compared to analyst estimates of $1.89 million. On average, equities analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Transactions at Taysha Gene Therapies

In related news, CEO Sean P. Nolan sold 41,312 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $4.61, for a total value of $190,448.32. Following the sale, the chief executive officer owned 2,908,257 shares in the company, valued at $13,407,064.77. This represents a 1.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Kamran Alam sold 23,849 shares of Taysha Gene Therapies stock in a transaction on Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $109,943.89. Following the transaction, the chief financial officer owned 1,443,786 shares of the company’s stock, valued at $6,655,853.46. The trade was a 1.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 598,623 shares of company stock valued at $2,822,188 in the last ninety days. 3.78% of the stock is currently owned by corporate insiders.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of TSHA. Caitong International Asset Management Co. Ltd raised its holdings in Taysha Gene Therapies by 698.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,577 shares of the company’s stock worth $141,000 after buying an additional 22,373 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $920,000. Invesco Ltd. increased its position in shares of Taysha Gene Therapies by 376.3% during the fourth quarter. Invesco Ltd. now owns 1,332,780 shares of the company’s stock valued at $7,330,000 after acquiring an additional 1,052,987 shares in the last quarter. Oracle Investment Management Inc. purchased a new position in Taysha Gene Therapies in the 4th quarter worth approximately $1,458,000. Finally, Voloridge Investment Management LLC bought a new position in Taysha Gene Therapies in the 4th quarter valued at approximately $301,000. 77.70% of the stock is currently owned by institutional investors.

Key Stories Impacting Taysha Gene Therapies

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Q4 beats on both EPS and revenue — reported EPS of ($0.08) vs. consensus ($0.11) and revenue $5.49M vs. $1.89M consensus; management reiterated progress in the business update. Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Clinical milestone — dosing continuing in the REVEAL pivotal trial for TSHA‑102, enrollment advancing across sites and on track to complete dosing in Q2 2026; company outlined a 2026 BLA submission path, which materially de‑risks the program if timelines hold. Taysha Gene Therapies, Inc. (TSHA) Q4 2025 Earnings Call Transcript
• Positive Sentiment: Balance sheet & liquidity highlighted — management and coverage notes emphasize a strong cash position and high current/quick ratios, supporting near‑term trial execution without obvious financing pressure. Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlights: Strong Cash Position and …
• Positive Sentiment: Analyst support — Chardan Capital reaffirmed a “buy” and set a $12 price target, signaling bullish conviction from at least one boutique healthcare analyst. Benzinga
• Neutral Sentiment: Earnings call coverage and transcripts are available for deep dives — useful for investors wanting management color on timelines, enrollment details and regulatory strategy. Taysha Gene Therapies Signals Momentum in Earnings Call
• Neutral Sentiment: Preview/coverage pieces summarize expectations and questions investors should watch on upcoming milestones (e.g., final pivotal enrollments, data timelines). Taysha (TSHA) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Company remains unprofitable with a very negative net margin and negative return on equity; biotech risk remains high if clinical or regulatory timelines slip — these fundamentals temper valuation despite the recent positive headlines. Taysha Gene Therapies Stock Earnings Details

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.